Phaseline

Targets › TSPO

TSPO (Translocator protein): drug programs, companies and trials

11 programs from 10 companies in 16 trials: 9 Phase 1, 7 Phase 2; Neurology, Other, Cardiovascular; next expected readout Nov 2026.

Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism, but its precise physiological role is controversial. (UniProt, P30536)

Open in Phaseline: the race on TSPO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Columbia University11C-ER176
TSPO radioligand
TSPOPhase 2Alzheimer DiseaseDec 2026
Hospices Civils de Lyon[18F]DPA-714
TSPO (translocator protein) PET tracer for imaging neuroinflammation
TSPOPhase 2CAROTID STENOSISDec 2026
Massachusetts General Hospital[11C]PBR28
TSPO PET imaging agent
TSPOPhase 2Chronic Pain; Blast InjuryAug 2027
Imperial College LondonXBD173
TSPO (18 kDa Translocator Protein) agonist
TSPOPhase 2Heathly VolunteersSep 2028
St. Jude Children's Research Hospital[18F]DPA-714
TSPO PET imaging tracer
TSPOPhase 2Brain TumorOct 2035
University of California, Davis[18F]DPA-714
TSPO (translocator protein) PET imaging tracer
TSPOPhase 1Epilepsy, Post-TraumaticNov 2026
University of Alabama at Birmingham[F-18]AV-1451
Translocator protein (TSPO) ligand for PET imaging
TSPOPhase 1Idiopathic Pulmonary Fibrosis; Alzheimer DiseaseJun 2027
University of Alabama at Birmingham[F-18]DPA-714
TSPO (18 kDa translocator protein) ligand PET tracer
TSPOPhase 1Fibromyalgia; Parkinson DiseaseApr 2028
The University of Texas Health Science Center, Houston[11C]PBR-28
TSPO (translocator protein) PET radiotracer for imaging microglial activation
TSPOPhase 1Neuropsychiatric SyndromesAug 2028
University of North Carolina, Chapel Hill[18F] PBR111
Translocator protein (TSPO) PET imaging tracer
TSPOPhase 1Concussion, BrainAug 2028
Yale University[11C]PBR28
TSPO radiotracer for imaging microglial activation and neuroimmune status
TSPOPhase 1HIV Associated Neurocognitive DisorderDec 2028

Conditions

Alzheimer Disease (3) Idiopathic Pulmonary Fibrosis (2) CAROTID STENOSIS (1) Brain Tumor (1) Chronic Pain (1) Blast Injury (1) Concussion, Brain (1) Epilepsy, Post-Traumatic (1) HIV Associated Neurocognitive Disorder (1) Neuropsychiatric Syndromes (1) Fibromyalgia (1) Parkinson Disease (1)

Modalities

small molecule (11)

Companies

University of Alabama at Birmingham (2) Hospices Civils de Lyon (1) St. Jude Children's Research Hospital (1) Massachusetts General Hospital (1) Columbia University (1) University of North Carolina, Chapel Hill (1) University of California, Davis (1) Yale University (1) The University of Texas Health Science Center, Houston (1) Imperial College London (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.